

Organised by





European Federation for Colposcopy



Hellenic Society for Colposcopy & Cervical Pathology



An afternoon of EUROPEAN COLPOSCOPY



WEB EVENT

Friday 20 October 2023 17:00 - 21:00 (Athens time, CET+1)

Dedicated to

Jo Jordan & Walter Prendiville




INVITATION

Dear colleagues and friends,



Personally, along with many other people involved in **Colposcopy & Cervical Pathology in Europe**, I hold great respect for two remarkable gentlemen, namely Jo Jordan and Walter Prendiville, who through their kindness, politeness, and nobility, have further elevated their academic and clinical accomplishments. They serve as an inspiring model for younger generations of medical doctors, and we believed the time had come for them to be honoured simultaneously.




Here we stand today, joined by many important individuals who have enthusiastically accepted the invitation to this event. We believe that this excitement clearly indicates a common interest in the significance of this topic and as such a thorough discussion is due. The intention would be to develop a consensus around the evidence base and the clinical / translational research that still needs to be done. Within this frame, we will also value the insight of Joe Jordan and Walter Prendiville and their wisdom on the key issues.

With best regards,

Professor Evangelos Paraskevaidis MD, PhD

Ioannina Medical School, Dept. OB-GYN

President -Hellenic Society of Colposcopy & Cervical Pathology (HSCCP)











An afternoon of

European Colposcopy

A Workshop on Long Term Outcomes Following Treatment of CIN

Topics

Preclinical and Clinical Evidence on Risk of Preterm Delivery Cervical Neo-Carcinogenecis Level of Awareness Balance of Risk to be Achieved

By European Expert Consensus Review and Discussion

Dedicated to

Jo Jordan and Walter Prendiville

for their lifetime offer and dedication to the European and Global Cervical Pathology and Colposcopy























OPENING 17:00-17:15

Evangelos Paraskevaidis/HSCCP. HECPA Emmanuel Diakomanolis/EFC. HSCCP Maggie Cruickshank/EFC Joseph Monsenego/EUROGIN Jean-Luc Mergui/IFCPC Joe Jordan/EFC.BSCCP Walter Prendiville/IARC, IFCPC



17:15-18:30

PRETERM DELIVERY

Chairs: Joe Jordan, Walter Prendiville, Pierre Martin-Hirsch, Emmanouel Diakomanolis, Xavier Carcopino

(In an historical order)

Comparison of Treatment methods: Cochrane Syst. Rev. 2000 Pierre Martin-Hirsch, Evangelos Paraskevaidis, H. Kitchener

Prematurity after excisional treatment, Lancet 2006 Maria Kyrgiou

Severe prematurity & perinatal mortality, BMJ 2008 Marc Arbyn

Fertility after excisional treatment, BMJ 2014 Anita Mitra

Prematurity according to the depth of excision, BMJ 2016 Maria Paraskevaidi

Consensus Terminology for Cone Dimensions, Lancet Oncol 2022 Xavier Carcopino

NHS Guidelines Pierre Martin-Hirsch









ANTENATAL CONSIDERATIONS

Chairs: Maria Kyrgiou, Apostolos Mamopoulos, Errikos Moulias
High risk clinics, risk prediction of PD, management in future pregnancies
Phillip Bennett

18:30-19:00 COFFEE BREAK

19:00-19:50 CERVICAL NEO-CARCINOGENECIS

Chairs: Jacob Bornstein, Deirdre Lyons, Maggie Cruickshank, Fani Groziou

(In an historical order)

Invasive Cx Ca after conservative treatment, Lancet 1997

Evangelos Paraskevaidis

Long-term risk of invasive cervical cancer, **Int J Cancer 2005**Theodoros Panoskaltsis

Risk of Cx & Vaginal Ca after Tx, **BMJ 2005** (Strander **BMJ 2007 & 2014**) *Ilkka Kalliala*

Incidence and mortality from Cx Ca and other malignancies after treatment of CIN, **Ann of Oncol 2020**Sarah Bowden

The Crypt Theory, **EJOGRB 2021**

Antonis Athanasiou, Evangelos Paraskevaidis

Elimination of reserve cells for prevention cervical cancer, **Virus Res 2023**Olaf Reich

Long term risk of prematurity v. risk of Cx Ca: a NETWORK Meta-analysis, Lancet Oncol 2022

Areti Angeliki Veroniki, Antonios Athanasiou

















DISCUSSION PANEL

Chairs: Evangelos Paraskevaidis, Joe Jordan, Maggie Cruickshank, Alexandros Mortakis

Can treatment modalities and colposcopy technique improve adverse long-term outcomes?

Have we got the balance of risk, right?

Improving risk stratification to select for treatment.

Treatment techniques:

- -Do current methods recognize the pathophysiology of disease?
- -Is preterm birth risk inevitable or preventable?

Commentators:

Evangelos Paraskevaidis, Joe Jordan, Walter Prendiville, Pierre Martin-Hirsch, Peter Sasieni, Vesna Kesić, Wiebren Tjalma, Joseph Monsenego, Jean-Luc Mergui, Marc Arbyn, Mara Kyrgiou, Jacob Bornstein, Deirdre Lyons, Maggie Cruickshank, Xavier Carcopino, Theo Panoskaltsis, Robert Jach, Olaf Reich, Andrea Ciavanttini, Anna Batistatou

Future Research (preterm delivery, post-op invasive cancer) that might result in improvement of outcomes Marc Arbyn, Mara Kyrgiou

























